YUKI ROSENKOETTER: Open Payments
NPI 1487744009 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,313 in 96 payments from 16 companies in 2025. Trend: 2023 $1,739 · 2024 $7,745 · 2025 $3,313
Food & beverage: $2,293Speaker / faculty: $1,020
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $1,095 |
| ABBVIE INC. | 32 | $713 |
| Gilead Sciences, Inc. | 9 | $403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $213 |
| Janssen Biotech, Inc. | 9 | $184 |
| Celltrion USA Inc. | 9 | $158 |
| GENZYME CORPORATION | 4 | $126 |
| Intercept Pharmaceuticals, Inc. | 4 | $85 |
| AstraZeneca Pharmaceuticals LP | 3 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
Products named: REZDIFFRA, MAVYRET, LINZESS, TREMFYA, DUPIXENT, ENTYVIO, RINVOQ, VEGZELMA.
Industry payments across CA — which companies pay providers there.
